Metabolic Syndrome as a Risk Factor for Idiosyncratic Drug-Induced Autoimmune Hepatitis (DIAIH) Following Nitrofurantoin Exposure

Dana Bielopolski1, Yifat Snir3, Marius Braun3,4, Michal Cohen3,4, Hagar Banai3, Ana Tobar2,4, Amir Shlomai1,3,4, Ran Tur-Kaspa1,3,5 and Assaf Issaschar1,3

1Departments of Medicine D, Rabin Medical Center-Beilinson Hospital, Petach Tikva
2Pathology, Rabin Medical Center-Beilinson Hospital, Petach Tikva
3The Liver Institute, Rabin Medical Center-Beilinson Hospital, Petach Tikva
4Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
5Faculty of Medicine Bar-Ilan university, Ramat Gan, Israel

*Corresponding Author: Dana Bielopolski, Internal Medicine D, Rabin Medical Center, Beilinson Campus, Israel.

Received: November 04, 2020; Published: July 28, 2021

Abstract

Background: Non-alcoholic fatty liver (NAFLD) and metabolic syndrome have been characterized as a risk factors for drug induced liver injury (DILI). Drug-induced autoimmune hepatitis (DIAIH) is a potentially fatal disease, with a wide variety of causative drugs, one of the most common is Nitrofurantoin used for prevention of urinary tract infection. Despite its idiosyncratic pattern of damage, there is no consensus regarding which patients are at increased risk to develop DIAIH following exposure.

Methods and Results: Reviewing our institution’s medical records between 2000 - 2015 we identified 11 patients who presented with hepatitis following long-term treatment with nitrofurantoin, exhibiting a mixed pattern of elevated liver enzymes. Liver biopsies revealed heavy plasma cells infiltrates and bridging necrosis. Cessation of nitrofurantoin, and administration of steroids normalized liver function tests and reversed symptoms. Prevalence of metabolic syndrome was double then expected among our patients.

Conclusion: Nitrofurantoin can cause idiosyncratic DIAIH in patients with metabolic syndrome and should be considered as a risk factor. In the presence of metabolic syndrome or fatty liver, alternative preventive treatment options for urinary tract infection should be sought, otherwise quarterly laboratory follow-up is advised to recognize early and potentially reversible liver damage.

Keywords: DILI; Hepatotoxicity; Nitrofurantoin; Fatty Liver

Abbreviations

AIH: Autoimmune Hepatitis; DIAIH: Drug Induced Autoimmune Hepatitis; DILI: Drug Induced Liver Injury; NAFLD: Nonalcoholic Fatty Liver Disease

Introduction

Drug induced liver injury (DILI) is an important complication that can occur through use of prescribed medicines, diet supplements or herbal products as alternative medicine. Risk factors of DILI are complex and interrelated; Females [1], the elderly [2] patients with...
underlying chronic liver disease [3], obesity and HIV [4] are at greater risk for DILI. Drug characteristics (e.g. medication dose, extent of hepatic metabolism, and drug lipophilicity) also contribute to the DILI risk [5].

Although still controversial, there is accumulating clinical evidence linking nonalcoholic fatty liver disease (NAFLD) with an increased risk or poorer outcome of DILI, independently of other confusing factors. This seems to apply more to certain types of intrinsic DILI (e.g. that are induced by acetaminophen, MTX and volatile anesthetics) than to idiosyncratic DILI, where clinical evidence is even more scarce and circumstantial [6].

Drugs that cause DILI can trigger immune which can lead to a clinical course similar to autoimmune hepatitis (AIH) [7]. Many drugs have been reported to cause this condition, which is named drug-induced AIH (DIAIH) [8-10], Nitrofurantoin being one of the prominent [11-13].

This potentially fatal disease is similar in many aspects to classical autoimmune hepatitis (AIH), with the exception that a drug is identified as the causative agent [14]. Patients developing DIAIH are not different from patients with AIH in terms of histology, serological findings, and treatment response [8], with one fundamental difference - there are no relapses in cases of DIAIH when immunosuppression is discontinued. This stands in sharp contrast to the high relapse rate after withdrawal of immunosuppression in AIH, which in most cases remains a chronic disease [8].

Nitrofurantoin is an antibiotic used in the treatment of recurrent urinary tract infection (UTI) known to cause idiosyncratic hepatotoxicity, where the dose-response curve lies to the right of the lethal dose. However, a sporadically occurring sensitivity factor, such as a fatty liver environment, could shift the dose-response curve for hepatotoxicity to the left, thereby bringing hepatotoxic doses into the therapeutic range [15].

We assembled a series of patients who presented with DIAIH following long-term treatment with nitrofurantoin and in whom an increased prevalence of the Metabolic Syndrome and fatty liver were observed.

**Methods**

We reviewed Rabin Medical Center liver institute files and hospitalization charts between the years 2000 - 2015 with the help of the institute physicians and identified patients which suffered hepatic injury as a result of prolonged nitrofurantoin exposure.

**Results**

Reviewing our institution files between the years 2000 - 2015 revealed eleven female patients, mean age 71.5 (range 64 - 84), community residents, and independent in terms of ADL activities, that were evaluated for severe and acute hepatitis.

Their chronic co-morbidities included hypertension (63.6%), diabetes (37%) and dyslipidemia/fatty liver (63.6%). Frequent medications used were mainly anti-hypertensives (See supplementary table 1 for complete description). All patients were treated with nitrofurantoin, 100 mg/day, for urinary tract infection, for periods of 2 months to 3 years before presentation.
Eight patients (72%) presented with symptoms of weight loss, anorexia, shortness of breath, and abdominal discomfort. Ascites and jaundice were prominent findings on physical examination observed in 5 patients. Three patients were asymptomatic and were admitted for evaluation of elevated liver enzyme levels on routine blood test (Table 1).

<table>
<thead>
<tr>
<th>Patient</th>
<th>p1</th>
<th>p2</th>
<th>p3</th>
<th>p4</th>
<th>p5</th>
<th>p6</th>
<th>p7</th>
<th>p8</th>
<th>p9</th>
<th>p10</th>
<th>p11</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST u/l</td>
<td>282</td>
<td>1302</td>
<td>848</td>
<td>1177</td>
<td>839</td>
<td>349</td>
<td>364</td>
<td>459</td>
<td>101</td>
<td>103</td>
<td>218</td>
</tr>
<tr>
<td>ALT u/l</td>
<td>81</td>
<td>603</td>
<td>545</td>
<td>1150</td>
<td>512</td>
<td>407</td>
<td>905</td>
<td>529</td>
<td>135</td>
<td>82</td>
<td>358</td>
</tr>
<tr>
<td>ALP u/l</td>
<td>99</td>
<td>603</td>
<td>148</td>
<td>320</td>
<td>130</td>
<td>355</td>
<td>116</td>
<td>152</td>
<td>101</td>
<td>119</td>
<td>82</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>2.71</td>
<td>15.4</td>
<td>14.5</td>
<td>3.87</td>
<td>2.31</td>
<td>4.7</td>
<td>1.91</td>
<td>4.9</td>
<td>0.91</td>
<td>0.8</td>
<td>0.5</td>
</tr>
<tr>
<td>Albumin g/dl</td>
<td>3.2</td>
<td>2.4</td>
<td>3</td>
<td>3.5</td>
<td>2.8</td>
<td>3.2</td>
<td>4.4</td>
<td>2.8</td>
<td>3.9</td>
<td>3.5</td>
<td>-</td>
</tr>
<tr>
<td>INR</td>
<td>1.71</td>
<td>1.3</td>
<td>1.41</td>
<td>1.25</td>
<td>1.33</td>
<td>1.03</td>
<td>1.06</td>
<td>1.4</td>
<td>1.06</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>antiSM u/l</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
<td>-</td>
<td>Positive</td>
<td>-</td>
<td>1:20</td>
<td>Negative</td>
<td>-</td>
<td>Negative</td>
<td></td>
</tr>
<tr>
<td>antiLKM u/l</td>
<td>0.7</td>
<td>0.6</td>
<td>0.9</td>
<td>-</td>
<td>0.9</td>
<td>-</td>
<td>-</td>
<td>0.6</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IgG Globulin mg/dl</td>
<td>4.2</td>
<td>2.9</td>
<td>5</td>
<td>3.9</td>
<td>6.4</td>
<td>-</td>
<td>-</td>
<td>3.8</td>
<td>3.79</td>
<td>3.1</td>
<td>-</td>
</tr>
</tbody>
</table>

**Table 1:** Laboratory data of patients prior to investigation, correlating the day of admission. (-) parameter was not tested. AST: Aspartate Transaminase, ALT: Alanine Transaminase, ALP: Alkaline Phosphatase, INR: International Normalized Ratio, ANA: Antinuclear Antibody, antiSM: Anti Smooth Muscle, antiLKM: Anti Liver Kidney Antigen.

Upon admission, all patients had a mixed pattern of elevated liver enzymes, both hepatocellular and cholestatic. Aminotransferase levels were 2 to 10 times the upper limit of normal and Bilirubin was elevated. Synthetic liver functions were abnormal in 63% of patients. Eight patients (72%) had elevated anti-nuclear antibody levels, with titers as high as 1:640. Seven patients (63%) had elevated globulin levels (mean 4.1 gr/dl, range 3.8 - 6.4) (Table 2).

<table>
<thead>
<tr>
<th>Patient</th>
<th>p1</th>
<th>p2</th>
<th>p3</th>
<th>p4</th>
<th>p5</th>
<th>p6</th>
<th>p7</th>
<th>p8</th>
<th>p9</th>
<th>p10</th>
<th>p11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitrofurantoin (dose mg)</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Nitrofurantoin duration (years)</td>
<td>3</td>
<td>2</td>
<td>0.2</td>
<td>0.2</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>0.5</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Steroid dose (mg)</td>
<td>30</td>
<td>30</td>
<td>9 mg (budeson)</td>
<td>20</td>
<td>60</td>
<td>40</td>
<td>-</td>
<td>40</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Steroid therapy duration (months)</td>
<td>3</td>
<td>8</td>
<td>-</td>
<td>4</td>
<td>7</td>
<td>2</td>
<td>-</td>
<td>Current</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 2:** Nitrofurantoin therapy prior to investigation and steroid therapy following diagnosis. Prednisone dose was given daily.

Citation: Dana Bielopolski, et al. “Metabolic Syndrome as a Risk Factor for Idiosyncratic Drug-Induced Autoimmune Hepatitis (DIAIH) Following Nitrofurantoin Exposure”. *EC Pharmacology and Toxicology* 9.8 (2021): 14-21.
All patients underwent ultrasonography. The most prominent abnormality identified, in 37% of patients, was a grainy or fatty liver texture. Liver biopsy, performed in 8 patients (72%), revealed heavy cellular infiltrates in all cases, with 5 patients showing plasma cells and 3 showing bridging necrosis in addition to portal fibrosis (Figure 1). Due to the random nature of biopsies, fatty components were negligible. Detailed description of histology and imaging is available in supplementary table 2.

Figure 1: Histopathological sample from a Liver biopsy of patient 5 showing drug induced autoimmune hepatitis (DIAIH). A- H&E staining, X40, showing heavy lymphocyte infiltrate in liver tissue. B- Masson stained liver tissue, X10, showing large area of fibrosis. C- H&E stained liver tissue, X100, exemplifying plasma cell infiltrate.

Cessation of nitrofurantoin was the initial treatment step in all patients, followed in 7 (63%) by administration of steroids (prednisone 0.5 - 1 mg/kg), and in one due to diabetes, budesonide 9 mg. Steroids were used for 2 to 6 months, followed by a slow tapering down. Patients were followed by the Liver Institute until liver function tests normalized, during which time they were clinically asymptomatic.

Discussion and Conclusion

Pre-existing liver disease seems not to be associated with increased risk of idiosyncratic hepatotoxicity when assessed for the bulk of medications. However, it could pose increased risk of hepatotoxicity when exposed to certain drugs including acetaminophen [16,17] several antibiotics (piperacillin/tazobactam, telithromycin) [18], the antithrombotic agent ticlopidine [19] and the antihypertensive agent losartan [18]. Interaction of a drug with a sporadically occurring inflammatory episode could explain the unpredictable onset of idiosyncratic adverse drug reactions and their apparent lack of relationship to dose [15]. We describe eleven female patients, chronically treated with nitrofurantoin for recurrent UTI, who developed severe hepatic injury after extended exposure to the drug. Severity of damage was assessed either by clinical deterioration, laboratory data, biopsy findings, or a combination of these parameters. In all cases, withholding the offending drug and in some cases adjacent treatment with steroids, reversed the damage as exemplified by laboratory values normalization and clinical improvement.

Bjornsson and colleagues described 24 patients with DIAIH, 11 of them were treated with nitrofurantoin. Their female patients were very similar to the cohort we describe in terms of demographic characteristics, exposure duration, clinical course and recovery.
did not witness relapse after steroids withdrawal [8]. DIAIH associated with nitrofurantoin rarely progresses to cirrhosis as hepatitis does not recur upon secession of the stimuli [20].

Another retrospective study observed that 15% of AIH were in fact drug induced, three fourths of cases were attributed either to nitrofurantoin or statins. The authors describe nitrofurantoin induced DIAIH with uniquely prolonged exposure, average latency time as long as one year. Of note, the long latency did not affect clinical outcome [21].

The degree of elevation in liver enzymes has poor correlation with severity of liver disease. Instead, the pattern of liver disease indicates near term and long-term consequences. The cholestatic pattern of hepatitis has the lowest mortality but may lengthen time for normalization of liver tests. Additionally, cholestatic and mixed hepatitis pattern have a small but definite risk of evolution to chronicity [22]. We were struck by the high prevalence of fatty liver, evidenced by radiological documentation, and metabolic syndrome components in our cohort. This finding could account, at least in part, to the susceptibility of our patients to adverse reaction of medication.

In patients with obesity, diabetes, insulin resistance, and nonalcoholic steatohepatitis, the metabolic environment characterized by reduced ATP synthesis and higher ROS levels can increase cytotoxicity [23,24]. These chronic conditions and illnesses predispose drug associated induction of cellular oxidative stress [25]: obesity, insulin resistance, and NAFLD increase cellular oxidants [26], fatty liver increases lipid peroxidation and [27] obesity, insulin resistance, and NAFLD are related to cellular antioxidation [28]. NAFLD and its main associated comorbidity, obesity, may be intertwined with drug - there is increasing awareness of potential DILI risk factors in NAFLD patients for a growing number of drugs [18,28]. In the context of obesity and related metabolic diseases, NAFLD could serve as a background for acute hepatitis, following drug exposure, where the combination increase formation of toxic metabolites [29]. For example, acetaminophen overdose could cause acute liver injury in patients with NAFLD more often than in non NAFLD patients [16].

In conclusion, our patients exhibit double the prevalence rate expected, implying a circumstantial connection between the two. Past series did not relate to this medical condition, and a possible relationship is yet to be elucidated. NAFLD is the most common cause of liver disease worldwide with prevalence increasing in parallel with that of obesity and diabetes [30]. Exposing patients with NAFLD or metabolic syndrome to long term nitrofurantoin treatment could cause acute hepatitis, similar to AIH, related to increased formation of toxic metabolites [29]. However, unlike AIH, drug cessation and in some cases a course of steroids treatment resulted in complete resolution with no clinical or laboratory relapses.

**Future Perspective**

Clinicians should be aware that DIAIH can occur in an idiosyncratic manner and avoid missing a diagnosis with catastrophic consequences [22]. A clinical background of metabolic syndrome in general and NAFLD in particular should be considered as a risk factor for nitrofurantoin induced AIH. Susceptible patients must undergo basic screening prior to treatment, including liver sonography and a blood marker, s/p cholecystectomy, OA
gastroesophageal reflux, GERD, s/p cholelithiasis, s/p IDC, cholelithiasis

**Financial Support**

No financial support was received in the preparation of this manuscript.

---

** Patients’ co-morbidities (supplementary table 1)**

<table>
<thead>
<tr>
<th>P1</th>
<th>P2</th>
<th>P3</th>
<th>P4</th>
<th>P5</th>
<th>P6</th>
<th>P7</th>
<th>P8</th>
<th>P9</th>
<th>P10</th>
<th>P11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyper-tension, hyperlipidemia, dia- phragmatic hernia, s/p cholecys-tectomy, OA</td>
<td>Hyperthyroidism, hyperlipidemia</td>
<td>Diabetes, osteoporosis, pace-maker, fatty liver, obesity, dyslipidemia</td>
<td>Fatty liver, hypertension, dyslipidemia, GERD, s/p chole-cystectomy</td>
<td>Hyper-tension, dyslipidemia, diabe- tes</td>
<td>Epilepsy</td>
<td>Hyper-tension, dyspepsia, IFG</td>
<td>Hypertension, diabetes, dyslipidemia, HLD, ost-eopoulosis, fatty liver</td>
<td>Reflux, CHF</td>
<td>Hypertension, OA, bilateral varicose veins, di-lated tho- racic aorta, hypothyroidism, s/p IDC, choleli-thiasis</td>
<td>Hyperthyroidism</td>
</tr>
</tbody>
</table>

** Patients’ symptoms (supplementary table 1)**

<table>
<thead>
<tr>
<th>P1</th>
<th>P2</th>
<th>P3</th>
<th>P4</th>
<th>P5</th>
<th>P6</th>
<th>P7</th>
<th>P8</th>
<th>P9</th>
<th>P10</th>
<th>P11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascites, pleural effusion, weight loss</td>
<td>Weakness, malaise, jaundice, ascites</td>
<td>Weakness, jaundice, anorexia, confusion</td>
<td>Routine checkup</td>
<td>Weight loss, anorexia,</td>
<td>Weight loss, hepatitis, hepatic encephalopathy, jaundice</td>
<td>Nausea, metallic taste, reflux</td>
<td>Anorexia, weight loss, jaundice</td>
<td>Cough, metallic taste, weight loss</td>
<td>Routine follow-up</td>
<td>Asympto-matric</td>
</tr>
</tbody>
</table>

---

**Citation:** Dana Bielopolski, et al. "Metabolic Syndrome as a Risk Factor for Idiosyncratic Drug-Induced Autoimmune Hepatitis (DIAIH) Following Nitrofurantoin Exposure". EC Pharmacology and Toxicology 9.8 (2021): 14-21.
**Patients’ medications (supplementary table 1)**

<table>
<thead>
<tr>
<th>P1</th>
<th>P2</th>
<th>P3</th>
<th>P4</th>
<th>P5</th>
<th>P6</th>
<th>P7</th>
<th>P8</th>
<th>P9</th>
<th>P10</th>
<th>P11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spinnolactone, amlodipin, zuclopenthixol, dekinet, amitryptiline, folic acid, omeprazole, simvastatin, tramades, tribemin</td>
<td>Atorvastatin, eltroxin, zopiclone, omeprazole, urso</td>
<td>Calcium vitamin d, escitalopram, amlodipine, valsartan, alendronate, lansoprazole, pregabalin, metformin, micropirin, repaglinide, simvastatin</td>
<td>Calcium, ester, atenolol, amiodipine, omeprazole, ramipril, simvastatin</td>
<td>Alendronate, calcium carbonate, tolterodine tartrate, metformine</td>
<td>Topiramate, carbamazepine, chlobazam, caltrate, eladronate</td>
<td>Micropirin, lansoprazole, vitamin B12</td>
<td>Metformine, micropirin, isoosorbide mononitrate, atenolol, losartan</td>
<td>Fusid, micropirin, esomeprazole</td>
<td>Silazapril, elandroxinate, vitamin+d, micropirin, mebeverine hydrochloride, atenolol, eltroxin, simvastatin</td>
<td>Eltroxin, bisoprolol, micropirin, candesartan</td>
</tr>
</tbody>
</table>

**Patients’ imaging (supplementary table 2)**

<table>
<thead>
<tr>
<th>P1</th>
<th>P2</th>
<th>P3</th>
<th>P4</th>
<th>P5</th>
<th>P6</th>
<th>P7</th>
<th>P8</th>
<th>P9</th>
<th>P10</th>
<th>P11</th>
</tr>
</thead>
<tbody>
<tr>
<td>US-liver size normal, lobular borders, grainy texture</td>
<td>US liver not enlarged, grainy texture, 1.3 cm cyst in the right lobe and a hypoechoic area 1/7 cm to be further evaluated by three phase CT</td>
<td>US - liver size normal, fatty texture, bile ducts not distended, pancreas size and echogenicity normal, spleen not enlarged, homogeneous, kidneys normal size, echogenicity and parenchyma, no hydro-nephrosis, no ascites</td>
<td>US - liver size normal, fatty texture, bile ducts not distended, pancreas size and echogenicity normal, spleen not enlarged, homogeneous, kidneys normal size, echogenicity and parenchyma, no hydro-nephrosis, no ascites</td>
<td>US - liver size normal, bile ducts normal, fatty liver</td>
<td>US - liver size normal, CBD diameter 1 cm with slight widening of the central intrahepatic bile ducts</td>
<td>US -Liver and bile ducts normal, fatty liver</td>
<td>US -liver and bile ducts normal, fatty liver</td>
<td>US - liver and bile ducts normal, fatty liver</td>
<td>US - liver and bile ducts normal, fatty liver</td>
<td>US - liver and bile ducts normal, fatty liver</td>
</tr>
</tbody>
</table>

**Supplementary Table 1**

**Patients’ imaging (supplementary table 2)**

<table>
<thead>
<tr>
<th>P1</th>
<th>P2</th>
<th>P3</th>
<th>P4</th>
<th>P5</th>
<th>P6</th>
<th>P7</th>
<th>P8</th>
<th>P9</th>
<th>P10</th>
<th>P11</th>
</tr>
</thead>
<tbody>
<tr>
<td>US-liver size normal, lobular borders, grainy texture</td>
<td>US liver not enlarged, grainy texture, 1.3 cm cyst in the right lobe and a hypoechoic area 1/7 cm to be further evaluated by three phase CT</td>
<td>US - liver size normal, fatty texture, bile ducts not distended, pancreas size and echogenicity normal, spleen not enlarged, homogeneous, kidneys normal size, echogenicity and parenchyma, no hydro-nephrosis, no ascites</td>
<td>US - liver size normal, fatty texture, bile ducts not distended, pancreas size and echogenicity normal, spleen not enlarged, homogeneous, kidneys normal size, echogenicity and parenchyma, no hydro-nephrosis, no ascites</td>
<td>US - liver size normal, bile ducts normal, fatty liver</td>
<td>US - liver size normal, CBD diameter 1 cm with slight widening of the central intrahepatic bile ducts</td>
<td>US - liver size normal, bile ducts normal, fatty liver</td>
<td>US - liver size normal, bile ducts normal, fatty liver</td>
<td>US - liver size normal, bile ducts normal, fatty liver</td>
<td>US - liver size normal, bile ducts normal, fatty liver</td>
<td>US - liver size normal, bile ducts normal, fatty liver</td>
</tr>
</tbody>
</table>

**Citation:** Dana Bielopolski, et al. “Metabolic Syndrome as a Risk Factor for Idiosyncratic Drug-Induced Autoimmune Hepatitis (DIAIH) Following Nitrofurantoin Exposure”. *EC Pharmacology and Toxicology* 9.8 (2021): 14-21.
Patients’ histology – supplementary table 2

<table>
<thead>
<tr>
<th></th>
<th>P1</th>
<th>P2</th>
<th>P3</th>
<th>P4</th>
<th>P5</th>
<th>P6</th>
<th>P7</th>
<th>P8</th>
<th>P9</th>
<th>P10</th>
<th>P11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibrosis with plasma cell infiltrate</td>
<td>Severe hepatitis with areas of panlobular necrosis</td>
<td>Not performed</td>
<td>Ex-tended hepatitis, majority of plasma cells, fibrosis</td>
<td>Heavy infiltrates, with fibrotic component, bridging necrosis</td>
<td>Not performed</td>
<td>Portal edema and fibrosis with septal formation, moderate activity including plasma cells and mild bile duct damage</td>
<td>Chronic hepatitis, moderate activity including plasma cells, with portal fibrosis</td>
<td>Not performed</td>
<td>Portal and mild lobular hepatitis, with portal fibrosis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Bibliography


Citation: Dana Bielopolski, et al. “Metabolic Syndrome as a Risk Factor for Idiosyncratic Drug-Induced Autoimmune Hepatitis (DIAIH) Following Nitrofurantoin Exposure”. EC Pharmacology and Toxicology 9.8 (2021): 14-21.


Volume 9 Issue 8 August 2021
©All rights reserved by Dana Bielopolski., et al.